Tesamorelin (Visceral Fat)

Single EGRIFTA WR1.28mg SC dose in healthy subjects, same label study. Original2mg Egrifta26/38min values came after14days, not this single-dose WR formulation.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

0.1833333 hours

Absorption half-life assumed

0.06452204 hours

Reference amount for the relative scale

1 mg

• The faster rate is inferred to match the 0.15 h source-scoped peak time; absorption half-life 0.06452204183467626 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Peak/Tmax/tail reconstruction gives AUC1.7866ng·h/mL versus1.172reported (+52.4%); do not call all endpoints reproduced.
• Either explicitly identify WR in model scope or keep generic formulation relative; never relabel saved2mg inputs as1.28mg.
• No additional F multiplier because peak includes availability.
• Source variability is large; means of endpoints need not define one typical individual curve.

• EGRIFTA WR US label March2025,12.3

  Healthy single1.28mgSC: Cmax3831pg/mL,Tmax.15h,t1/2 11min,AUCinf1172pg·h/mL. WR and SV are not substitutable; exposure at WR1.28mg resembles original Egrifta2mg.

• Original EGRIFTA label2010,12.3

  Original2mgSC single dose peak2874.6pg/mL in healthy subjects;26min tail reported after14consecutive doses. OriginalSC F<4%, not50%.

tesamorelin-relative-timing-2026-10 · version 1